pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity

Peptides

Volumn 28, Issue 4, 2007, Pages 935-948

  Kohn, Wayne D ^a   Micanovic, Radmila ^a   Myers, Sharon L ^a   Vick, Andrew M ^a   Kahl, Steven D ^a   Zhang, Lianshan ^a   Strifler, Beth A ^a   Li, Shun ^a   Shang, Jing ^a   Beals, John M ^a   Mayer, John P ^a   DiMarchi, Richard D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Basal insulin; Blood glucose control; Receptor selectivity

Indexed keywords

AMINO ACID; ARGININE; GLYCINE; INSULIN DERIVATIVE; INSULIN GLARGINE; LYSINE; SOMATOMEDIN C RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN CELL; INSULIN SYNTHESIS; ISOELECTRIC POINT; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RECEPTOR BINDING; SOLUBILITY;

3T3-L1 CELLS; AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ARGININE; BINDING, COMPETITIVE; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DOGS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISOELECTRIC POINT; LYSINE; MALE; MICE; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RADIOIMMUNOASSAY; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; STRUCTURE-ACTIVITY RELATIONSHIP;

CANIS FAMILIARIS;

EID: 33847364416     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.01.012     Document Type: Article

References (49)

1. Bahr M., Kolter T., Seipke G., and Eckel J. Growth promoting and metabolic activity of the human insulin analog [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 320 (1997) 259-265
2. Berti L., Kellerer M., Bossenmaier B., Seffer E., Seipke G., and Haring H.U. The long acting human insulin analog HOE 901: characteristics of insulin signaling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30 (1998) 123-129
3. Bolli G.B., and Owens D.R. Insulin glargine. Lancet 356 (2000) 443-445
4. Bolli G.B., DiMarchi R.D., Park G.D., Pramming S., and Koivisto V.A. Insulin analogs and their potential in the management of diabetes mellitus. Diabetologia 42 (1999) 1151-1167
5. Bornfeldt K.E., Gidlof R.A., Wasteson A., Lake M., Skottner A., and Arnqvist H.J. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34 (1991) 307-313
6. Bott S., Bott U., Berger M., and Mulhauser I. Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 40 (1997) 926-932
7. Brange J., and Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35 (1999) 307-335
8. Ciaraldi T.P., Carter L., Seipke G., Mudaliar S., and Henry R.R. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-1. J Clin Endocrinol Metab 86 (2001) 5838-5847
9. Clement S., and Bowen-Wright H. Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report. Diab Care 25 (2002) 1479-1480
10. Darrington R.T., and Anderson B.D. Evidence for a common intermediate in insulin deamidation and covalent dimer formation: effects of pH and aniline trapping in dilute acidic solutions. J Pharm Sci 84 (1995) 275-282
11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
12. Doyle E.A., Weinzimer S.A., Steffen A.T., Ahern J.A.H., Vincent M., and Tamborlane W.V. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diab Care 27 (2004) 1554-1558
13. Geiger R., and Enzmann F. Clinical application of insulin derivatives. In: Baba S., Kaneko T., and Yanaihara N. (Eds). Proceedings of the symposium on proinsulin, insulin and C-peptide (1978), Tokushima Excerpta Medica, Amsterdam 306-310
14. Gin H., and Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diab Metab 31 (2005) 7-13
15. 2: a new retard principle based on a natural proinsulin-derived processing intermediate. Diab Res Clin Pract 1 (1985) S204
16. Hamann A., Matthaei S., Rosak C., et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with Type I diabetes. Diab Care 26 (2003) 1738-1744
17. Hamilton-Wessler M., Ader M., Dea M., Moore D., Jorgensen P.N., Markussen J., et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 42 (1999) 1254-1263
18. Hansen B.F., Danielsen G.M., Drejer K., Sorensen A.R., Wiberg F.C., Klein H.H., et al. Sustained signalling from the insulin receptor after stimulation with insulin analogs exhibiting increased mitogenic potency. Biochem J 315 (1996) 271-279
19. Hermanson K., Madsbad S., Perrild H., Kristensen A., and Axelsen M. Comparison of the soluble basal insulin analog detemir with NPH insulin. A randomized open crossover trial in Type 1 diabetic subjects on basal-bolus therapy. Diab Care 24 (2001) 298-301
20. Hofmann F., and Garcia-Echeverria C. Blocking insulin-like growth factor-1 receptor as a strategy for targeting cancer. Drug Discov Today 10 (2005) 1041-1047
21. Home P. Insulin glargine: the first clinically useful extended-acting insulin in half a century?. Expert Opin Invest Drugs 8 (1999) 307-314
22. Hordern S.V.M., Wright J.E., Umpleby A.M., Shojaee-Moradie F., Amiss J., and Russell-Jones D.L. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16 h euglycemic clamp. Diabetologia 48 (2005) 420-426
23. Jehle P.M., Micheler C., Jehle D.R., Breting D., and Boehm B.O. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 354 (1999) 1604-1607
24. Jorgensen L.N., Dideriksen L.H., and Drejer K. Carcinogenic effect of the human insulin analogue B-10 Asp in female rats. Diabetologia 35 Suppl. 1 (1992) A3
25. Kurtzhals P., Schaffer L., Sorensen A., Kristensen C., Janassen I., Schmid C., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (2000) 999-1005
26. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
27. Le Roith D. Insulin-like growth factors. N Engl J Med 336 (1997) 633-640
28. Markussen J., Hougaard P., Ribel U., Sorensen A.R., and Sorensen E. Soluble, prolonged-acting insulin derivatives, I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng 1 (1987) 205-213
29. Markussen J., Diers I., Engesgaard A., Hansen M.T., Hougaard P., Langkjaer L., et al. Soluble, prolonged-acting insulin derivatives, II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. Protein Eng 1 (1987) 215-223
30. Markussen J., Diers I., Hougaard P., Langkjaer L., Norris K., Snel L., et al. Soluble, prolonged-acting insulin derivatives, III. Degree of protraction and crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng 2 (1988) 157-166
31. Markussen J., Havelund S., Kurtzhals P., Anderson A.S., Halstrom J., Hasselager E., et al. Soluble fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39 (1996) 281-288
32. McAulay V., and Frier B. Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycemia in patients with diabetes. Expert Opin Pharmacother 5 (2004) 2-3
33. Oiknine R., Bernbaum M., and Mooradian A.D. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 65 (2005) 325-340
34. Owens D.R., Zinman B., and Bolli G.B. Insulins today and beyond. Lancet 358 (2001) 739-746
35. Pieber T.R. Long-acting insulin analogues: can they provide a basal insulin level?. J Pediatr Endocrinol Metab 12 (1999) 745-750
36. Pieber T.R., Eugene-Jolchine I., Derobert E., et al. Efficacy and safety of HOE901 versus NPH insulin in patients with type I diabetes. Diab Care 23 (2000) 157-162
37. Pieber T.R., Draeger E., Kristensen A., and Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diab Med 22 (2005) 850-857
38. Plank J., Bodenlenz M., Sinner F., Magnes C., Gorzer E., Regittnig W., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diab Care 28 (2005) 1107-1112
39. ε-palmitoyl Lys(B29)] human insulins in subjects with IDDM. Diabetologia 41 (1998) 116-120
40. Rosen P., Simon M., Reinauer H., Friesen H.J., Diaconescu C., and Brandenburg D. Binding of insulin to bovine liver plasma membrane. Use of insulin analogues modified at the A1 residue. Biochem J 186 (1980) 945-952
41. Rosenstock J., Schwartz S.L., Clark Jr. C.M., Park G.D., Donley D.W., and Edwards M.B. Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diab Care 24 (2001) 631-636
42. Seipke G., Geison K., Neubauer H.P., Pittius C., Roskamp R., and Schwabe D. New insulin preparations with prolonged action profiles: A21-modified arginine insulins. Diabetologia 35 Suppl. 1 (1992) A4
43. Seipke G., Berchtold H., Geisen K., et al. HOE901-a new insulin with prolonged action. Eur J Endocrinol 132 Suppl. 1 (1995) 25
44. Slieker L.J., Brooke G.S., DiMarchi R.D., Flora D.B., Green L.K., Hoffmann J.A., et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 40 Suppl. 2 (1997) S54-S61
45. Staiger K., Hennige A.M., Schweitzer M.A., Staiger H., Haring H.U., and Kellerer M. Effect of insulin glargine versus regular human insulin on proliferation of human breast epithelial cells. Diabetes 54 Suppl. 1 (2005) A111
46. Sundby F. Separation and characterization of acid-induced insulin transformation products by paper electrophoresis in 7 M urea. J Biol Chem 237 (1962) 3406-3411
47. Tanford C., and Epstein J. The physical chemistry of insulin. I. Hydrogen ion titration curve of zinc-free insulin. J Am Chem Soc 76 (1954) 2163-2169
48. Vaag A., Handberg A., Laurizen M., Henriksen J.E., Pederson K.D., and Beck-Nielsen H. Variation in absorption of NPH insulin due to intramuscular injection. Diab Care 13 (1990) 74-76
49. Vague P., Selam J.-L., Skeie S., De Leeuw I., Elte J.W.F., Haahr H., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with Type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diab Care 26 (2003) 590-596